Effect of Lidocaine Block on Gastroesophageal Reflux Disease

Launched by MUHAMMAD · Mar 5, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating whether a treatment called Stellate Ganglion Block can help improve symptoms of Gastroesophageal Reflux Disease (GERD). GERD is a condition that causes stomach acid to flow back into the esophagus, leading to discomfort and other symptoms. The researchers want to find out if adding this treatment to regular rehabilitation training can provide better relief for patients' symptoms compared to rehabilitation alone.

To be eligible for the study, participants must be between 18 and 80 years old and have a diagnosis of GERD. They should be able to comfortably move their neck while sitting and have stable vital signs. However, people with certain health issues, such as a history of gastric cancer or recent neck injuries, cannot participate. The study will last for 10 days, during which some participants will receive the Stellate Ganglion Block daily in addition to their rehabilitation treatment. Throughout the trial, researchers will ask questions and gather information to see if the treatment helps improve GERD symptoms.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Gastroesophageal Reflux Disease diagnosis
• • aged between 18 and 80 years old.
• • subjects who tolerate cervical movements in sitting position.
• • stable vital signs.
• • normal consciousness
• Exclusion Criteria:
• • contraindications for stellate ganglion block.
• • peptic ulcer.
• • previous or present gastric cancer.
• • previous gastric surgery.
• • recent fractures or cervical trauma.